MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

Sponsor
Lepu Biopharma Co., Ltd.
Study ID
NCT07479485
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MRG006A — DRUG
    Administrated intravenously
  • Pucotenlimab — DRUG
    Administrated intravenously
  • Bevacizumab — DRUG
    Administrated intravenously
  • PD1/VEGF antibody — DRUG
    Administrated intravenously
  • TKI — DRUG
    Administrated intravenously

Study Details

This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).

Key Dates

First listed
Mar 18, 2026
Start date
Apr 8, 2026
Status verified
Jul 2026
Primary completion
Apr 30, 2028
Completion
Apr 30, 2029

Study Design

Enrollment
160 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: MRG006A+Pucotenlimab + Bevacizumab
  • Experimental: MRG006A+ PD1/VEGF antibody
  • Experimental: MRG006A+ TKI

Primary Outcome Measure

Adverse events [ Time Frame: Up to 2 years ]

Central Contacts

Find similar trials

Nationwide
Liver cancer trialsOncology trialsGI oncology trialsHepatology trials

Related Studies